| Literature DB >> 35265211 |
Lu Tang1,2, Jing Li1,2, Ting Pan1,2, Yue Yin1,2, Yijun Mei1,2, Qiaqia Xiao1,2, Ruotong Wang1,2, Ziwei Yan1,2, Wei Wang1,2.
Abstract
Despite the encouraging breakthroughs in medical development, cancer remains one of the principle causes of death and threatens human health around the world. Conventional treatment strategies often kill cancer cells at the expense of serious adverse effects or great pain, which yet is not able to achieve an effective cure. Therefore, it is urgent to seek for other novel anticancer approaches to improve the survival rate and life quality of cancer patients. During the past decades, nanotechnology has made tremendous progress in cancer therapy due to many advantages such as targeted drug delivery, decreased dosage-related adverse effects and prolonged drug circulation time. In the context of nanomedicine, carbon nanomaterials occupy very significant positions. Owing to their innate outstanding optical, thermal, electronic, and mechanic features, easy functionalization possibility and large surface for drug loading, carbon nanomaterials serve as not only drug carriers, but also multifunctional platforms to combine with diverse treatment and diagnosis modalities against cancer. Therefore, developing more carbon-based nanoplatforms plays a critical role in cancer theranostics and an update overview that summarizes the recent achievement of carbon nanomaterial-mediated anticancer theranostic approaches is of necessity. In this review, five typical and widely investigated carbon nanomaterials including graphene, graphdiyne, fullerene, carbon nanotubes and carbon quantum dots are introduced in detail from the aspect of treatment strategies based on both cancer cells and tumor microenvironment-involved therapeutic targets. Meanwhile, modern diagnostic methods and clinical translatability of carbon nanomaterials will be highlighted as well. © The author(s).Entities:
Keywords: Cancer theranostics, Nanotechnology; Carbon materials; Synergistic strategy; Targeted drug delivery
Mesh:
Substances:
Year: 2022 PMID: 35265211 PMCID: PMC8899561 DOI: 10.7150/thno.69628
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.556
Figure 9Representative structures of fullerene derivatives and their functions in cancer treatment. Fullerene-based nanosystems act as excellent candidates in cancer theranostics, showing diverse functions against cancer development including angiogenesis suppression, metastasis inhibition, ROS scavenging, immune activation and cell cycle regulation. Abbreviations: Gd, gadolinium; B cell, B lymphocyte; T cell, T lymphocyte; NK cell, natural killer cell; ECM, extracellular matrix; ROS, reactive oxygen species; NPs, nanoparticles.
Summary of carbon nanomaterials in cancer treatment
| Carbon nanomaterial | Therapeutic target/modulation | Drug delivery system | Therapeutic modality | Tumor therapy model | Effectiveness | Ref. |
|---|---|---|---|---|---|---|
| GO | Mitochondria | PTX@GO-PEG-OSA | PDT, PDT and Chemotherapy | HGC-27 gastric cancer | Induce mitochondrial damage, suppress the energy supply of P-gp, reverse the drug resistance of PTX |
|
| Cytoplasm | GO-PEI-miR-214 inhibitor | Gene therapy | Cal27 and SCC9 oral squamous cell carcinoma | Decrease OSCC cell invasion and migration, increase cell apoptosis by targeting PTEN and p53 |
| |
| Nucleus | C-dot-PEG-pDNA-TNF-α-CS-CGO | Gene therapy | Hela cervical cancer | Actively target tumor cells and deliver pDNA into the nucleus, generate anti-angiogenesis effect |
| |
| Immune cells | GO-PEI-R848-mRNA | Gene therapy and | B16 melanoma | Generate OVA-specific antibodies, decrease the tumor size and weight, prevent the lung metastasis |
| |
| Redox /pH/enzymatic responsive drug release | GGBD | PTT and | MCF-7 breast cancer | Release DOX in TME, improve the drug penetration ability and enhance intracellular delivery of drug |
| |
| GNR | Extracellular matrix | GNR-PEG-Ce6 | PAT | SKOV-3 ovarian cancer | Delay the disaggregation and spreading of ovarian cancer spheroids, reduce their adhesion to ECM protiens |
|
| GDY | Cytoplasm | GDY-CeO2-miR181a | Gene therapy | Esophageal squamous cell carcinoma | Facilitate DNA damage, relieve hypoxic tumor environment, and sensitize radiotherapy |
|
| GDYO | Nucleus | GDYO-CDDP/DOX@DSPE-PEG-MTX | PTT, PDT and Chemotherapy | Hela cervical carcinoma | Enhance active target ability and achieve excellent synergistic photo-chemotherapy effect |
|
| ROS modulation | rGDYO-Fe3O4-CREKA | PTT and Fenton reaction-mediated therapy | 4T1 breast cancer | Achieve synergistic PTT and Fenton reaction-mediated antitumor effect |
| |
| Tumor vasculature/Hypoxia | GDYO@i-RBM | PTT and PDT | EMT-6 breast cancer | Alleviate tumor hypoxia, improve blood perfusion, and achieve synergistic PDT and PTT effect |
| |
| C60 | Nucleus | Hexakis-glucosamine C60 (sweet-C60) | PDT | Pancreatic cancer | Enhance tumor targeting and exhibit strong photoactive and photodynamic cytotoxic effect |
|
| Lysosomal | C60-Dex-NH2 | Gene therapy | MDA-MB-231 breast cancer | Promote the lysosomal entrapment of siRNA and exhibit remarkable gene silencing efficiency |
| |
| Extracellular matrix | C60 nanofilms | Chemotherapy | HepG2 and C3A liver cancer | Suppress the proliferation of HCC cells and terminate their cell cycle |
| |
| C70 | Cytoplasm | C70-EDA | Chemotherapy | A549 lung cancer | Inhibit cancer cell migration, modulate intracellular MYH9 distribution, and hinder EMT process |
|
| Gd@C82 | Macrophages | β-alanines modified Gd@C82 | Immunotherapy | 4T1 breast cancer model and A549 lung cancer | Upregulate M1-related cytokines and protein expression, reduce the proliferation of tumor cells |
|
| SWNTs | Cytoplasm | SWNT-PS/siRNA | PTT and Gene therapy | Hela cervical cancer | Generate high gene transport capacity and achieve controlled gene release in tumor cells, exhibit high antitumor activity |
|
| Cytoplasm | SWNT-CY7-IGF-1Ra | PTT and | Pancreatic cancer | Achieve precise tumor-targeting therapy, increase the body weight and prolong the survival rate of tumor-bearing mice |
| |
| Mitochondria | SWNTs-PL-PEG-NH2 | TAT | H22 liver cancer | Selectively destruct tumor mitochondria, cause tumor cell apoptosis |
| |
| Cancer stem cells | / | Immunotherapy | MDA-MB-231 breast cancer | Realize active targetability toward breast CSCs |
| |
| MWNTs | Antigen-presenting cells | MWNTs-CpG-αCD40-OVA | Immunotherapy | B16F10 melanoma | Improve the co-loading ability of OVA, CpG and anti-CD40 Ig, inhibit tumor growth and metastasis |
|
| Tumor vasculature | iRGD-PEI-MWNT-SS-CD/pAT2 | Chemotherapy | A549 lung cancer | Result in significant tumor growth inhibition and neovascularization suppression |
| |
| CQDs | Nucleus | PEGylated CQD-DOX | Chemotherapy | HepG2 liver cancer | Accumulate in the nuclei of cancer cells and |
|
| Cytoplasm | Alkyl-PEI2k-Cdot | Gene therapy | 4T1 breast cancer | Promote pDNA delivery into the cytoplasm and |
| |
| Mitochondria | CQDs-TPGS-TPP | Chemotherapy | MCF-7 breast cancer | Inhibit MDR development and trigger tumor cell apoptosis |
| |
| Tumor vasculature | CQDs/Cu2O nanocomplexes | Chemotherapy | SKOV3 ovarian cancer | Hinder angiogenesis in TME and inhibit tumor cell growth and migration |
| |
| Extracellular matrix | CQDs-KD1 | Chemotherapy | MCF-7 and 4T1 breast cancer | Prolong retention time of KD1 in plasma and at the tumor site, effectively inhibit tumor growth and lung metastasis |
|
Abbreviations: CD40, clusters of differentiation 40; CDDP, cisplatin; C-dot, carbon dot; Ce6, chlorin e6; CpG, cytidine-phosphate-guanosine; CQD, carbon quantum dot; CSCs, cancer stem cells; Dex, dextran; DOX, doxorubicin; ECM, extracellular matrix; EDA, ethylenediamine; Gd, gadolinium; GDY, graphdiyne; GDYO, graphdiyne oxide; GNR, graphene nanoribbon; GO, graphene oxide; HCC, hepatocellular carcinoma; HGC-27, human gastric cancer cell-27; IGF-1Ra, insulin-like growth factor-1Ra; KD1, kunitz domain 1; MDR, multidrug resistance; MTX, methotrexate; MWNTs, multi-wall carbon nanotubes; MYH9, myosin heavy chain 9; OSA, oxidized sodium alginate; OSCC, oral squamous cell carcinoma; OVA, ovalbumin; pAT2, plasmid angiotensin II type 2 receptor; PAT, photoacoustic therapy; PDT, photodynamic therapy; PEI, polyetherimide; PEG, polyethylene glycol; P-gp, p-glycoprotein; PL, peptide lipid; PTEN, phosphatase and tensin homolog; PTT, photothermal therapy; PTX, paclitaxel; ROS, reactive oxygen species; SWNTs, single-wall carbon nanotubes; TME, tumor microenvironment; TNF-α, tumor necrosis factor-alpha; TPGS, D-α-tocopheryl polyethylene glycol succinate; TPP, triphenylphosphine.
Representative applications of carbon nanosystems in cancer imaging
| Type of Carbon nano systems | Imaging approach | Functionalized molecules | Tumor model | Ref. | |
|---|---|---|---|---|---|
| GO | Fluorescence Imaging | PEG, FA | B16F0 melanoma |
| |
| MRI | Gd, Au | HepG2 liver cancer |
|
| |
| MRI | Gd (III) | MCF-7 breast cancer |
| ||
| PAI | Cy5.5 | H1975 lung cancer |
|
| |
| Raman imaging | Au | Hela cervical cancer |
|
| |
| rGO | Radionuclide Imaging | PEG, 131I | 4T1 breast cancer |
| |
| PET | PEG, 1,4,7-triazacyclononane-1,4,7-triacetic acid, (NOTA),64Cu | MCF-7 breast cancer |
| ||
| NGO | NIRF imaging | PEG | Raji B-cell Burkitt's Lymhoma |
|
|
| Fullerene | NIRF imaging | HA | HCT 116 colon cancer |
|
|
| PAI | D-A antenna, DSPE-mPEG | Hela cervical cancer |
|
| |
| SWNTs | Raman Imaging | FA, PEG, Au | KB oral epithelial carcinoma |
|
|
| MRI | Aspargine-glycine-arginine (NGR) peptide, gadolinium-diethylenetriamine pentaacetic acid | MCF-7 breast cancer |
| ||
| PAI | / | Human breast cancer |
|
| |
| Radionuclide Imaging | PDA, PEG | 4T1 breast cancer |
|
| |
| NIRF imaging | Phospholipid-PEG | MDA-MB-468 breast cancer |
| ||
| MWNTs | MRI | FA, GdN | Hela cervical cancer |
| |
| Ultrasonography | Fe3O4, AuNPs | MCF-7 breast cancer |
|
| |
| PAI | RGD peptide, silica-coated gold nanorods | MGC803 gastric cancer |
| ||
| Radionuclide Imaging | Indium-111 | C57/B16 melanoma |
|
| |
| CQDs | Fluorescence imaging | AS141, Ce6 | Hela cervical cancer |
|
|
| Fluorescence imaging | silica NPs, L-cysteine | HEp-2 laryngeal |
|
|
Abbreviations: AuNPs, Au nanoparticles; Ce6, chlorin e6; CQDs, carbon quantum dots; FA, folic acid; Gd, gadolinium; GdN, gadolinium nanoparticle; GO, graphene oxide; HA, hyaluronic acid; MRI: magnetic resonance imaging; MWNTs: multi-wall carbon nanotubes; NGO, nano graphene oxide; NGR, asparagine-glycine-arginine; NIRF, near-infrared fluorescence; NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid; PAI, photoacoustic imaging; PDA, polydopamine; PEG, polyethylene glycol; PET, positron emission tomography; rGO, reduced graphene oxide; SWNTs: single-wall carbon nanotubes.